This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -11.36% and 29.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
by Zacks Equity Research
Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.
Prothena (PRTA) Down 3.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst
by Zacks Equity Research
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.
Implied Volatility Surging for Prothena (PRTA) Stock Options
by Zacks Equity Research
Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.
Prothena Restructures Resources, to Cut Workforce by 57%
by Zacks Equity Research
Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.
Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.
Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength
by Zacks Equity Research
Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.
What's in Store for Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena (PRTA) has faced quite a few setbacks in the year so far and hence investors will be focused on management's strategy when it reports first-quarter results next week.
Implied Volatility Surging for Prothena (PRTA) Stock Options
by Zacks Equity Research
Prothena (PRTA) needs investors to pay close attention to the stock based on moves in the options market lately.
Acorda Files Parkinson's Drug Marketing Application in EU
by Zacks Equity Research
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
Prothena Rallies on Multi-Year Collaboration With Celgene
by Zacks Equity Research
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
Options Traders Expect Huge Moves in Prothena (PRTA) Stock
by Zacks Equity Research
Investors in Prothena (PRTA) need to pay close attention to the stock based on moves in the options market lately.
Prothena (PRTA) Up 8.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Accepts Acorda's NDA for Parkinson's Disease Candidate
by Zacks Equity Research
FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.
Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?
by Zacks Equity Research
Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.
Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops
by Zacks Equity Research
Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.
Acorda Reports Death in Parkinson's Trials, Stock Down 40%
by Zacks Equity Research
Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.
Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.
What's in the Cards for Prothena (PRTA) in Q3 Earnings?
by Zacks Equity Research
Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.
Prothena's Psoriasis Candidate Disappoints in Phase I Study
by Zacks Equity Research
Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.